IP Library › Granted Patent US 9,155,699
Granted Patent B2
US 9,155,699 · App. 14/055,959 · Granted Oct 13, 2015

Pulmonary delivery for levodopa

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,155,699
App. No.
14/055,959
Granted
Oct 13, 2015
Kind
B2
Abstract

In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Claims (16)

1. A composition of dry powder particles formulated for pulmonary delivery comprising about 75 weight percent levodopa or more and sodium chloride.

2. The composition of claim 1 , wherein the particles further comprise a phospholipid or a combination of phospholipids.

3. The composition of claim 1 , wherein the particles have a tap density about 0.4 g/cm 3 or less.

4. The composition of claim 1 , wherein the particles have a volume median geometric diameter about 5 micrometers or more.

5. The composition of claim 1 , wherein the particles have an aerodynamic diameter of from about 1 micrometer to about 5 micrometers.

6. The composition of claim 1 , wherein the particles have an aerodynamic diameter of from about 1 micrometer to about 3 micrometers.

7. The composition of claim 1 , wherein the particles have an aerodynamic diameter of from about 3 micrometer to about 5 micrometers.

8. The composition of claim 1 , wherein the particles have a tap density about 0.3 g/cm 3 or less.

9. The composition of claim 1 , wherein the particles have a tap density about 0.2 g/cm 3 or less.

10. The composition of claim 1 , wherein the particles have a tap density about 0.1 g/cm 3 or less.

11. The composition of claim 1 , wherein the particles comprise about 10% or less by weight of sodium chloride.

12. The composition of claim 1 , wherein the particles comprise about 5% or less by weight of sodium chloride.

13. The composition of claim 1 , wherein the particles comprise about 2% or less by weight of sodium chloride.

14. The composition of claim 2 , wherein the phospholipid is dipalmitoyl phosphatidylcholine (DPPC).

15. A composition of dry powder particles consisting of about 75% or more levodopa, sodium chloride and dipalmitoylphosphatidylcholine.

16. A composition of dry powder particles consisting of levodopa, sodium chloride and dipalmitoylphosphatidylcholine, wherein the ratio of levodopa:dipalmitoylphosphatidylcholine:sodium chloride is about 90:8:2.